Show simple item record

dc.contributor.authorMorake, Mokhitli
dc.contributor.authorWentzel, Johannes F.
dc.contributor.authorWong, Ho Ning
dc.contributor.authorSmit, Frans J.
dc.contributor.authorN'Da, David D.
dc.contributor.authorHaynes, Richard K.
dc.date.accessioned2019-03-26T06:58:53Z
dc.date.available2019-03-26T06:58:53Z
dc.date.issued2018
dc.identifier.citationMorake, M. et al. 2018. Preliminary evaluation of artemisinin-cholesterol conjugates as potential drugs for the treatment of intractable forms of malaria and tuberculosis. ChemMedChem, 13(1):67-77. [ https://doi.org/10.1002/cmdc.201700579]en_US
dc.identifier.issn1860-7179
dc.identifier.issn1860-7187 (Online)
dc.identifier.urihttp://hdl.handle.net/10394/32040
dc.identifier.urihttps://onlinelibrary.wiley.com/doi/10.1002/cmdc.201700579
dc.identifier.urihttps://doi.org/10.1002/cmdc.201700579
dc.description.abstractTo evaluate the feasibility of developing drugs that may be active against both malaria and tuberculosis (TB) by using in part putative cholesterol transporters in the causative pathogens and through enhancement of passive diffusion in granulomatous TB, artemisinin–cholesterol conjugates were synthesized by connecting the component molecules through various linkers. The compounds were screened in vitro against Plasmodium falciparum (Pf) and Mycobacterium tuberculosis (Mtb). Antimalarial activities (IC50) against Pf drug‐sensitive NF54, and drug‐resistant K1 and W2 strains ranged from 0.03–2.6, 0.03–1.9, and 0.02–1.7 μm. Although the compounds are less active than the precursor artemisinin derivatives, the cholesterol moiety renders the compounds relatively insoluble in the culture medium, and variation in solubilities among the different compounds may reflect in the range of efficacies observed. Activities against Mtb H37Rv were assessed using a standardized colony‐forming unit (CFU) assay after 24 h pretreatment of cultures with each of the compounds. Percentage inhibition ranged from 3–38 % and 18–52 % at 10 and 80 μm, respectively. Thus, in contrast to the comparator drug artemether, the conjugates display enhanced activities. The immediate aims include the preparation of conjugates with enhanced aqueous solubilities, assays against malaria and TB in vivo, and for TB, assays using an infected macrophage model and assessment of granuloma influxen_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.subjectArtemisininsen_US
dc.subjectCholesterolen_US
dc.subjectConjugatesen_US
dc.subjectMalariaen_US
dc.subjectTuberculosisen_US
dc.titlePreliminary evaluation of artemisinin-cholesterol conjugates as potential drugs for the treatment of intractable forms of malaria and tuberculosisen_US
dc.typeArticleen_US
dc.contributor.researchID20134045 - Wentzel, Johannes Frederik
dc.contributor.researchID25904442 - Wong, Ho Ning
dc.contributor.researchID20926588 - Smit, Frans Johannes
dc.contributor.researchID20883072 - N'Da, David Dago
dc.contributor.researchID22966390 - Haynes, Richard Kingston
dc.contributor.researchID25933787 - Morake, Mokhitli Zacharia


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record